Bismarck, North Dakota 58501
701-751-1128 http://www.legacypharmaresearch.com legacy@midconetwork.com
RESEARCH CENTER OVERVIEW
Legacy Pharma Research believes that good clinical practice is an international, ethical and scientific quality standard for designing, conducting, recording and reporting trials that involve the participation of humans. Legacy is dedicated to compliance with these standards and assures the rights, safety, well being and confidentiality of trial patients are protected. Legacy has staff trained and updated on as part of our ongoing commitment, consistent with the Declaration of Helsinki, to ensure clinical trial data are credible and accurate. Legacy Pharma Research has experience in all phases of clinical research.
Legacy Pharma Research Staff
All research staff have experience, knowledge and training to conduct clinical trials according to FDA regulations and Good Clinical Practices. Although a Principal Investigator and lead coordinator are responsible for each trial, the research department works together as a team to facilitate the safe and efficient conduct of trials. On-call research coverage is available on a 24/7 basis.
Dr. Thomas D. Davis, PharmD - Director of Business Development 30 years of research experience
Dr. Greg Pfister, PharmD - Director of Neurosciences
18 years of research experience
Michelle Dannenfelzer - Certified Clinical Research Coordinator
6 years of research experience
Jennifer Steffan - Oncology Research Coordinator- Certified Clinical Research Coordinator
8 years of research experience
Lindsay Tollefson - VP Legacy, Certified Clinical Research Coordinator
10 years of research experience
Diane Davis - President, Legacy, Administration
20 years office management
PATIENT DEMOGRAPHICS: Bismarck, North Dakota is the medical referral center for a multi-state region serving an urban and rural 300,000+ population base.
Cardiology/Vascular Diseases
Endocrinology
Gastroenterology
Hematology
Immunology/Infectious Diseases
Musculoskeletal
Nephrology/Urology
Neurology
Obstetrics/Gynecology
Oncology
Ophthalmology
Otolaryngology
Pediatrics/Neonatology
Pharmacology/Toxicology
Psychiatry/Psychology
Pulmonary/Respiratory Diseases
Rheumatology
Our office located in Bismarck, North Dakota is centrally located and is within two blocks of two large medical centers and several clinics.
- Centralized operations and management
- Single point of contact for sponsors
- "Preferred" status with CROs
- Dedicated Project Managers for all therapeutic areas
- ACRP certified coordinator team
- Technology Support Center
- Patient Recruitment/Advertising Department
- Ongoing Investigator and Coordinator Education Programs
EQUIPMENT
- Centrifuge
- Lab Processing Area
- Freezer (-20, -70C)
- Multiple refrigerators
- EKGs
LAB ACCESS
Northern Plains Laboratory, accredited by the "gold standard" in the laboratory industry: The Laboratory Accreditation Program of the College of American Pathologists. The CAP Laboratory Accreditation Program (LAP) is recognized by the JCAHO and CMS/CLIA has granted the CAP LAP deeming authority to ensure that CAP - accredited laboratories fulfill or exceed the hundreds of national standards reflecting the best practice in the industry.
Dr. Tom Davis
Director of Business Development
Legacy Pharma Research
601 N. 5th Street
Bismarck, ND 58501
USA
701-751-1128
701-751-1131 (fax)
tdavis.legacy@midconetwork.com
www.legacypharmaresearch.com
- Advanced Non-Small Cell Lung Cancer
- Advanced Ovarian Cancer
- Advanced Stage Non-small Cell Lung Cancer
- Chemotherapy Induced Anemia in Patients with Metastatic Breast Cancer
- Metastatic Colorectal Cancer with wild-type KRAS tumors.
- MS - Central Neuropathic Pain due to Multiple Sclerosis
- MS - Central Neuropathic Pain due to Multiple Sclerosis
- Myelodysplastic Syndrome (MDS)
- Myelofibrosis
- Newly Diagnosed Mantle Cell Lymphoma who are not eligible for a bone marrow transplant.
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy
- Prostate Cancer
- Type 2 Diabetes and Acute Coronary Syndrome